<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451828</url>
  </required_header>
  <id_info>
    <org_study_id>MM2277</org_study_id>
    <nct_id>NCT00451828</nct_id>
  </id_info>
  <brief_title>Cholesterol and Pharmacogenetic Study</brief_title>
  <acronym>CAP</acronym>
  <official_title>Cholesterol and Pharmacogenetic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital &amp; Research Center Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Francisco General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital &amp; Research Center Oakland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the CAP study was to determine genetic influences on efficacy of
      simvastatin treatment with regard to LDL cholesterol reduction and changes in other markers
      of cardiovascular disease risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite widespread use of statin therapy for reducing risk of cardiovascular disease risk,
      there is considerable inter-individual variation in statin efficacy, and it would be
      desirable to identify markers that would be predictive of the magnitude of beneficial
      response. The effect of statin most strongly associated with improved clinical outcomes is
      reduction in LDL cholesterol. The CAP study was a six week non-randomized, open label study
      of simvastatin 40 mg/day in a group of 335 African-American and 609 Caucasian volunteer
      subjects. Measurements of plasma lipids and lipoproteins, as well as other markers of
      cardiovascular disease risk, were obtained at the screening and entry visits, and after four
      and six weeks of simvastatin treatment. Both baseline measurements and changes in response to
      simvastatin therapy are being used to test for associations with genetic polymorphisms.
      Significant findings are being replicated in other study cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>-2, 0, 4, 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>-2, 0, 4, 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>-2, 0, 4, 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>-2, 0, 4, 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>-2, 0, 4, 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol/HDL Cholesterol</measure>
    <time_frame>-2, 0, 4, 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B</measure>
    <time_frame>-2, 0, 4, 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein AI</measure>
    <time_frame>-2, 0, 4, 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein CIII</measure>
    <time_frame>-2, 0, 4, 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Peak Particle size</measure>
    <time_frame>-2, 0, 4, 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Subfractions</measure>
    <time_frame>-2, 0, 4, 6 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>40mg/day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 30 years of age

          -  Total Cholesterol between 160 to 400 mg/dl

          -  &gt; 3 grandparents of African-American descent or &gt; 3 grandparents of Caucasian descent

          -  serum triglycerides &lt; 400 mg/dl

          -  fasting glucose &lt; 126 mg/dl

        Exclusion Criteria:

          -  Use of lipid-lowering medication

          -  Use of over-the-counter products containing sterol or stanol esters or fish oil

          -  Recent or planned change in dietary intake or weight change of more than 4.5 kg

          -  Use of corticosteroids, immunosuppressive drugs or drugs affecting the CYP3A4 system

          -  Known liver disease or elevated transaminase levels

          -  Elevated creatine phosphokinase levels &gt; 10 times upper limits of normal

          -  Uncontrolled blood pressure, or diabetes mellitus

          -  Abnormal renal or thyroid function

          -  Current alcohol or drug abuse

          -  Major illness in the preceding three months

          -  Pregnancy

          -  Know intolerance to statins

          -  Racial ancestry other than African-American or Caucasian
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M Krauss, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital &amp; Research Center Oakland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Simon JA, Lin F, Hulley SB, Blanche PJ, Waters D, Shiboski S, Rotter JI, Nickerson DA, Yang H, Saad M, Krauss RM. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol. 2006 Mar 15;97(6):843-50. Epub 2006 Jan 27.</citation>
    <PMID>16516587</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2007</study_first_submitted>
  <study_first_submitted_qc>March 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2007</study_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ronald M. Krauss, MD</name_title>
    <organization>Children's Hospital Oakland Research Institute</organization>
  </responsible_party>
  <keyword>Statins</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

